Genetic and Epigenetic Characterization of the Tumors in a Patient with a Tongue Primary Tumor, a Recurrence and a Pharyngoesophageal Second Primary Tumor

Overview

Journal Mol Cytogenet

Publisher Biomed Central

Specialty Biochemistry

Date 2017 Apr 18

PMID 28413448

Authors

Ilda P Ribeiro

Francisco Marques

Leonor Barroso

Jorge Migueis

Francisco Caramelo

Andre Santos

Maria J Juliao

Joana B Melo

Isabel M Carreira

Affiliations

Soon will be listed here.

Abstract

Background: The choice of therapeutic modality for oral carcinoma in recurrent or second primary tumors remains controversial, as the treatment modalities available might be reduced by the treatment of the first tumor, and the overall survival is lower when compared with patients with a single or first tumor. Identifying biomarkers that predict the risk of relapse and the response to treatment is an emerging clinical issue.

Case Presentation: A Caucasian 49-years-old man was treated with chemotherapy followed by chemoradiotherapy for a primary left side tongue tumor, achieving a complete response. After 49-months of follow-up, a local recurrence was diagnosed. After 3 months, a second primary tumor at the pharyngoesophageal region was detected. Genomic and epigenetic characterization of these three tumors was performed using array Comparative Genomic Hybridization, Multiplex Ligation-dependent Probe Amplification (MLPA) and Methylation Specific MLPA.

Results: The three tumors of this patient shared several imbalances in all chromosomes excluding chromosomes 9, 20 and 22, where genes related to important functional mechanisms of tumorigenesis are mapped. The shared genomic imbalances, such as losses at 1p, 2p, 3p, 4q, 5q, 6q, 7q, 8p, 10p, 11q, 12p, 12q, 13q, 15q, 16p, 16q, 17p, 17q, 18q, 19p, 19q, 21q and Xp and gains at 3q, 7q, 14q and 15q showed a common clonal origin for the diagnosed relapses. We identified some chromosomal imbalances and genes mapped in the chromosomes 2, 3, 4, 6, 7, 11, 14, 17, 18 and 22 as putative linked to chemoradioresistance and chemoradiosensitivity. We also observed that gains in short arm of chromosomes 6, 7, 8 and 18 were acquired after treatment of the primary tumor. We identified losses of gene and promoter methylation of and genes, as predictors of relapses.

Conclusions: A common clonal origin for the diagnosed relapses was observed and we identified some putative candidate biomarkers of prognosis, relapse risk and treatment response that could guide the development of management strategies for these patients.

References

Bossi P, Locati L, Licitra L . Emerging tyrosine kinase inhibitors for head and neck cancer. Expert Opin Emerg Drugs. 2013; 18(4):445-59. DOI: 10.1517/14728214.2013.842976. View

Gonzalez-Garcia R, Naval-Gias L, Roman-Romero L, Sastre-Perez J, Rodriguez-Campo F . Local recurrences and second primary tumors from squamous cell carcinoma of the oral cavity: a retrospective analytic study of 500 patients. Head Neck. 2009; 31(9):1168-80. DOI: 10.1002/hed.21088. View

Schrock A, Bode M, Goke F, Bareiss P, Schairer R, Wang H . Expression and role of the embryonic protein SOX2 in head and neck squamous cell carcinoma. Carcinogenesis. 2014; 35(7):1636-42. DOI: 10.1093/carcin/bgu094. View

Cabanillas R, Astudillo A, Valle M, de la Rosa J, Alvarez R, Duran N . Novel germline CDKN2A mutation associated with head and neck squamous cell carcinomas and melanomas. Head Neck. 2011; 35(3):E80-4. DOI: 10.1002/hed.21911. View

Sabbir M, Roy A, Mandal S, Dam A, Roychoudhury S, Panda C . Deletion mapping of chromosome 13q in head and neck squamous cell carcinoma in Indian patients: correlation with prognosis of the tumour. Int J Exp Pathol. 2006; 87(2):151-61. PMC: 2517352. DOI: 10.1111/j.0959-9673.2006.00467.x. View

Ghosh A, Ghosh S, Maiti G, Sabbir M, Zabarovsky E, Roy A . Frequent alterations of the candidate genes hMLH1, ITGA9 and RBSP3 in early dysplastic lesions of head and neck: clinical and prognostic significance. Cancer Sci. 2010; 101(6):1511-20. PMC: 11159363. DOI: 10.1111/j.1349-7006.2010.01551.x. View

van den Broek G, Wreesmann V, van den Brekel M, Rasch C, Balm A, Rao P . Genetic abnormalities associated with chemoradiation resistance of head and neck squamous cell carcinoma. Clin Cancer Res. 2007; 13(15 Pt 1):4386-91. DOI: 10.1158/1078-0432.CCR-06-2817. View

Garnis C, Baldwin C, Zhang L, Rosin M, Lam W . Use of complete coverage array comparative genomic hybridization to define copy number alterations on chromosome 3p in oral squamous cell carcinomas. Cancer Res. 2003; 63(24):8582-5. View

Danahey D, Tobin E, Schuller D, Weghorst C, Lang J . p16 mutation frequency and clinical correlation in head and neck cancer. Acta Otolaryngol. 1999; 119(2):285-8. DOI: 10.1080/00016489950181837. View

10.

Noorlag R, van Kempen P, Stegeman I, Koole R, van Es R, Willems S . The diagnostic value of 11q13 amplification and protein expression in the detection of nodal metastasis from oral squamous cell carcinoma: a systematic review and meta-analysis. Virchows Arch. 2015; 466(4):363-73. PMC: 4392171. DOI: 10.1007/s00428-015-1719-6. View

11.

Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier A, Soussi T . p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol. 2000; 18(7):1465-73. DOI: 10.1200/JCO.2000.18.7.1465. View

12.

Gutierrez V, Alvarez Marcos C, Llorente J, Guervos M, Dominguez Iglesias F, Arguelles Tamargo L . Genetic profile of second primary tumors and recurrences in head and neck squamous cell carcinomas. Head Neck. 2011; 34(6):830-9. DOI: 10.1002/hed.21824. View

13.

van Kempen P, Noorlag R, Braunius W, Moelans C, Rifi W, Savola S . Clinical relevance of copy number profiling in oral and oropharyngeal squamous cell carcinoma. Cancer Med. 2015; 4(10):1525-35. PMC: 4618623. DOI: 10.1002/cam4.499. View

14.

Sano D, Myers J . Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev. 2007; 26(3-4):645-62. DOI: 10.1007/s10555-007-9082-y. View

15.

Markopoulos A . Current aspects on oral squamous cell carcinoma. Open Dent J. 2012; 6:126-30. PMC: 3428647. DOI: 10.2174/1874210601206010126. View

16.

Borkosky S, Gunduz M, Nagatsuka H, Beder L, Gunduz E, Ali M . Frequent deletion of ING2 locus at 4q35.1 associates with advanced tumor stage in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol. 2008; 135(5):703-13. DOI: 10.1007/s00432-008-0507-y. View

17.

Ribeiro I, Caramelo F, Marques F, Domingues A, Mesquita M, Barroso L . WT1, MSH6, GATA5 and PAX5 as epigenetic oral squamous cell carcinoma biomarkers - a short report. Cell Oncol (Dordr). 2016; 39(6):573-582. DOI: 10.1007/s13402-016-0293-5. View

18.

Brauswetter D, Danos K, Gurbi B, Felegyhazi E, Birtalan E, Meggyeshazi N . Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma. Virchows Arch. 2016; 468(5):579-87. DOI: 10.1007/s00428-016-1905-1. View

19.

Pickering C, Zhang J, Yoo S, Bengtsson L, Moorthy S, Neskey D . Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. 2013; 3(7):770-81. PMC: 3858325. DOI: 10.1158/2159-8290.CD-12-0537. View

20.

Cabanillas R, Llorente J . The Stem Cell Network model: clinical implications in cancer. Eur Arch Otorhinolaryngol. 2008; 266(2):161-70. DOI: 10.1007/s00405-008-0809-3. View